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ABSTRACT
The concept of cognitive reserve (CR) in Alzheimer’s disease (AD) explains the differences between individuals in their susceptibili-
ty to AD-related pathologies. An enhanced CR may lead to less cognitive deficits despite severe pathological lesions. Parkinson’s 
disease (PD) is also a common neurodegenerative disease and is mainly characterized by motor dysfunction related to striatal do-
paminergic depletion. The degree of motor deficits in PD is closely correlated to the degree of dopamine depletion; however, signifi-
cant individual variations still exist. Therefore, we hypothesized that the presence of motor reserve (MR) in PD explains the indi-
vidual differences in motor deficits despite similar levels of striatal dopamine depletion. Since 2015, we have performed a series of 
studies investigating MR in de novo patients with PD using the data of initial clinical presentation and dopamine transporter PET 
scan. In this review, we summarized the results of these published studies. In particular, some premorbid experiences (i.e., physical 
activity and education) and modifiable factors (i.e., body mass index and white matter hyperintensity on brain image studies) could 
modulate an individual’s capacity to tolerate PD pathology, which can be maintained throughout disease progression. 
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JMD
The concept of reserve was introduced to explain the mismatch 
between the degree of observed pathological changes in the brain 
and clinical manifestations.1 The most representative form of re-
serve is cognitive reserve (CR) that explains the differences be-
tween individuals in their susceptibility to age-related brain 
changes or Alzheimer’s disease (AD)-related pathologies.2 Epide-
miological studies suggest that lifelong experiences, including ed-
ucational and occupational attainment and participation in lei-
sure activities in later life, can enhance CR.2 Patients with high 
CR may exhibit fewer cognitive deficits despite having a similar 
level of AD pathology compared with those with low CR.2
Parkinson’s disease (PD) is also a common neurodegenera-
tive disease that affects the elderly. The main symptom of PD 
manifests as motor deficits, which is primarily related to stria-
tal dopaminergic depletion. Motor symptoms in PD do not 
develop until 50–60% of nigral dopaminergic neurons are lost,3 
suggesting the presence of compensatory mechanisms in the 
motor system. This compensatory ability (i.e., the ability of the 
brain to perform without functional impairment until damage 
reaches a critical threshold) is known as neural reserve4,5 and 
may differ among patients, reflecting an individual’s capacity to 
tolerate neuropathological lesions. In addition, the amount of 
motor deficits may differ among patients who have a similar 
level of striatal dopamine depletion. These features suggest the 
presence of motor reserve (MR) in PD, which explains the in-
dividual differences in parkinsonian motor deficits at similar 
levels of pathological changes. Here, we summarize a series of 
our publications investigating MR in PD.
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ASSESSMENT OF MR IN PD
Since 2009, dopamine transporter (DAT) scan using an [18F] 
N-(3-fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nor-
tropane (FP-CIT) positron emission tomography (PET) scan 
was performed as an initial evaluation for the diagnosis of PD 
in Yonsei Parkinson Center. When patients were drug-naïve, 
Part III of Unified Parkinson’s Disease Rating Scale (UPDRS-
motor) and the Mini-Mental State Examination (MMSE) were 
assessed in each patient to estimate their baseline PD motor se-
verity and baseline cognitive function, respectively. The final di-
agnosis of PD was made according to the clinical criteria of the 
UK Brain Bank,6 the presence of appropriate DAT defects on 
FP-CIT PET scans,7 and the presence of PD drug response dur-
ing follow-up (≥ 6 months). Patients with cognitive dysfunction 
(MMSE score < 24) were excluded from data analysis.
The detailed methods of PET-CT image acquisition and 
quantitative analyses of FP-CIT PET data were described previ-
ously.8 DAT activity was calculated in six striatal subregions: the 
ventral striatum, anterior caudate, posterior caudate, anterior 
putamen, ventral putamen and posterior putamen.7 Baseline 
UPDRS motor score and DAT activity in the posterior putamen 
or in the sensorimotor striatum were used to assess MR in each 
patient with PD. The degree of CR in AD is represented by clin-
ical severity and AD pathology.2 If the same concept is applied 
to PD, MR may be represented by the initial UPDRS motor 
score (i.e., clinical severity) and the level of dopamine depletion 
(i.e., PD pathology) (Figure 1A). However, because we could 
not measure the level of dopamine depletion based on FP-CIT 
PET data, the X-axis of the graph should be replaced by DAT 
activity in the posterior putamen, and MR could be plotted as 
demonstrated in Figure 1B. In this figure, patients with high 
MR exhibited fewer motor deficits, i.e., lower UPDRS motor 
score, compared with those with low MR despite similar levels 
of DAT activity in the posterior putamen.
PREMORBID EXPERIENCES AND MR
Exercise engagement
Animal experiments have demonstrated that physical train-
ing may protect dopamine neurons from various parkinson-
ism-inducing neurotoxins.9,10 Additionally, epidemiological 
studies have demonstrated that long-term strenuous exercises 
are associated with reduced development of PD in humans.11,12 
Accordingly, just as premorbid cognitive activity enhances an 
individual’s CR,2 premorbid physical activity (i.e., engagement 
in exercise) may enhance MR in individuals with PD. To ad-
dress this hypothesis, premorbid engagement of leisure-time 
exercise was assessed in 102 patients using the Physical Activity 
Scale for the Elderly.13 Among patients with mild to moderate re-
ductions in striatal dopaminergic activity (greater than the me-
dian DAT activity in the posterior putamen), the group with the 
highest exercise engagement showed significantly lower UPDRS 
motor scores (i.e., less parkinsonian motor deficits) despite hav-
ing similar levels of DAT activity compared to the middle and 
the lowest exercise engagement groups combined (Figure 2A). 
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Figure 1. Schematic drawing for representing MR in PD. A: Individuals with low MR might manifest parkinsonian symptoms at mild levels of 
PD pathology. B: When DAT activity in the posterior putamen is used as an indirect marker for the PD pathological burden, individuals with 
low MR would exhibit higher UPDRS motor scores at a similar level of DAT activity. MR: motor reserve, PD: Parkinson’s disease, DAT: do-
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Meanwhile, among the patients with severe reduction in striatal 
dopaminergic activity, the highest tertile exercise group showed 
significantly higher UPDRS motor scores, suggesting a more 
rapid decline in motor function related to decreases in striatal 
DAT activity compared with the other two groups. These results 
suggest that engagement in premorbid exercise acts as a proxy 
for an active reserve in the motor domain (i.e., MR) in patients 
with PD. A recent paper demonstrated delayed clinical mani-
festation of PD among physically active skiers, which supports 
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Figure 2. Premorbid experiences and MR. A: A scatterplot showing the relationship between DAT activity in the posterior putamen and mo-
tor deficits according to the premorbid physical activity. The highest tertile group (red) showed a significantly steeper slope compared with 
the middle tertile (green, p = 0.002) and the low tertile group (blue, p = 0.001), suggesting that engagement in premorbid exercise acts as a 
proxy for an active reserve in patients with PD [Adapted from Sunwoo et al. Parkinsonism Relat Disord 2017;34:49-53 (13)]. B: A scatterplot 
showing the relationship between DAT activity in the posterior putamen and motor deficits according to the level of education. Patients with 
higher education (closed circle) exhibited lower UPDRS motor scores compared to those with lower education (open circle) despite having 
a similar DAT activity in the posterior putamen (p = 0.032) [Adapted from figure from Sunwoo et al. J Neurol Sci 2016;362:118-120 (18)]. C: 
I. A scatterplot showing the relationship between DAT activity in the posterior putamen and motor deficits according to smoking status. Al-
though mean DAT activity in the posterior putamen (p = 0.016) and ventral putamen (p = 0.028) was higher in current smokers (red) com-
pared to ex-smokers (green) and never-smokers (blue), a similar slope of motor deficits relative to DAT activity among the groups suggests 
that current smoking does not enhance MR in individuals with PD. II. Comparison of longitudinal increases in LED according to smoking 
status. No significant differences in changes in LED were noted among the smoking groups (interaction between group and time, p = 
0.948), suggesting that current smoking has no additional clinical benefits in prognostic aspects [Adapted from Lee et al. Ann Neurol 
2017;82:850-854 (28)]. MR: motor reserve, DAT: dopamine transporter, PD: Parkinson’s disease, UPDRS: Unified Parkinson’s Disease 
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Educational attainment
Educational attainment is a main factor that enhances CR in 
AD.2 In PD populations, an epidemiological study identified 
an inverse relationship between the level of education and the 
risk of PD;15 however, others studies have reported inconsistent 
results.16,17 Therefore, similar to CR in AD, higher educational 
attainment could also be associated with enhanced MR in PD. 
In this study, a total of 182 patients were classified into 2 
groups: higher (≥ 12 years of education) and lower education 
(< 12 years of education).18 The higher education group exhib-
ited less severe parkinsonian motor deficits and lower DAT ac-
tivity in the posterior putamen than the lower education group 
despite a similar duration of PD symptoms. The difference in 
motor deficits between the groups remained significant after 
adjusting for potential confounding factors (i.e., age, sex, dis-
ease duration, and MMSE scores) as well as DAT activity in the 
posterior putamen as covariates (Figure 2B). These results sug-
gest that high education attainment could lead to enhanced 
MR in individuals with PD. Educational attainment has also 
been proposed as an MR proxy in other previous studies,19-22 
and a higher level of education possibly enhances MR via 
greater cerebral volume or white matter integrity, increased 
synaptic plasticity, more efficient recruitment of brain net-
works or recovery mechanisms,19,20 and beneficial effects on 
general health or environmental risk factors.21 
Smoking habits
Cigarette smoking is associated with a reduced risk of PD; a 
meta-analysis showed that current smokers have a relative risk 
of 0.39 for the development of PD.23 However, whether smok-
ing protects against the development of PD or PD itself pro-
tects against smoking remains controversial.24,25 In experimen-
tal animals, cigarette smoke protects against toxin-induced 
dopamine neuronal damage.26,27 However, it remains unknown 
whether smoking protects dopamine neuronal degeneration 
and subsequently enhances MR in humans with PD. Of the to-
tal 282 male patients with PD, current-smokers (n = 44) 
showed higher DAT activity in the posterior and ventral puta-
men but exhibited similar motor deficits compared to ex-
smokers (n = 105) and never-smokers (n = 133).28 Selective 
sparing of DAT activity in the posterior and ventral putamen 
was more pronounced in the more affected side than the less 
affected side, suggesting that smoking preferentially exerts a 
protective effect on dopamine neurons that are most affected 
by PD pathology. However, a similar slope of motor deficits 
relative to DAT activity in the posterior putamen suggests that 
smoking status is not associated with MR in individuals with 
PD (Figure 2C–I). Longitudinal change of levodopa-equivalent 
dose (LED) did not differ among the smoking groups (Figure 
2C–II), which suggests no additional clinical benefits related to 
current smoking. 
DEMOGRAPHIC VARIABLES AND MR
Age
Ample evidence suggests that age at PD onset is a major de-
terminant of clinical heterogeneity in patients with PD.29-31 
Young-onset PD has consistently demonstrated slower disease 
progression, better response to dopaminergic medications, 
more frequent motor complications, and less frequent cognitive 
impairments compared to old-onset PD.31 However, the mecha-
nism underlying the age at onset-dependent differences in PD 
remains unknown. Few reports have demonstrated that age at 
onset is associated with different patterns of striatal dopamine 
depletion in PD;32-35 however, these studies were limited by 
small sample size,33 confounding effects of PD medication,32,34 
and less detailed segmentation of the striatum.32-35 To investigate 
the relationship between age at onset and MR in PD, a total of 
205 patients were subdivided into tertile groups according to 
their age at onset of PD symptoms.36 The old-onset PD group 
(the highest tertile group, > 66 years, n = 73) exhibited higher 
UPDRS motor scores than the young-onset PD group (the low-
est tertile group, < 58 years, n = 66), but DAT activity in the 
posterior putamen was comparable between the two groups. 
The old-onset PD group exhibited an increased risk for devel-
oping freezing of gait and required higher doses of dopaminer-
gic medications for symptom control over time than the young-
onset group (Figure 3A–I and II). In an additional analysis, a 
general linear model showed that the old-onset group had sig-
nificantly more severe motor deficits than the young-onset 
group after controlling for sex, disease duration, and DAT ac-
tivity in the posterior putamen (p < 0.05) (Figure 3A–III). This 
finding suggests that the old-onset group represents poor MR 
in PD compared to the young-onset group. 
Sex
PD develops more often in males than in females; a meta-
analysis showed an increased relative risk of 1.5 in males.37 Age 
at PD onset is later in females than in males,38,39 which partly 
correlates with the fertile life span in females.39 Clinically, female 
PD patients exhibit less severe parkinsonian motor features and 
better levodopa responses with more severe levodopa-induced 
dyskinesia.40,41 However, whether sex is a critical risk factor for 
developing levodopa-induced dyskinesia remains controver-
sial.42-44 These sex differences suggest a beneficial influence of 
the female sex hormones (i.e., estrogen) against the development 
and progression of PD. The beneficial effect of estrogen could 
also enhance MR in individuals with PD, which may depend on 
MR in PD
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the patients’ age. Among a total of 307 patients,45 female PD pa-
tients (n = 155) exhibited greater DAT activity in all the striatal 
subregions than male PD patients (n = 152). Age-related DAT 
decline was greater in the anterior and posterior caudate and in 
the anterior putamen in female PD patients compared to male 
PD patients but similar in other subregions (Figure 3B). Sex dif-
ferences in age-related DAT decline in the antero-dorsal stria-
tum is presumably due to age-related decline in estrogen. How-
ever, this difference was not observed in the sensorimotor striatum, 
suggesting that female PD patients do not have a greater MR 
Figure 3. Demographic variables and motor reserve. A: I. Survival curves of the development of FOG in patients with young-onset PD (n = 
66) and old-onset PD (n = 73). The old-onset group demonstrated an increased risk for developing FOG compared with the young-onset 
group (p = 0.007). II. Comparison of longitudinal increases in LED according to age at onset. The old-onset group required higher doses of 
dopaminergic medications for symptom control compared with the young-onset group (interaction between group and time, p < 0.001). III. A 
scatterplot showing the relationship between DAT activity in the posterior putamen and motor deficits according to age of onset. The old-on-
set group (green circle) exhibited more severe motor deficits than the young-onset group (red circle) after controlling for sex, disease dura-
tion, and DAT activity in the posterior putamen (p = 0.016) [Adapted from Chung et al. J Mov Disord 2019;12:113-119 (36)]. B: Scatterplots 
showing the relationship between DAT activity in the striatal subregions and age of onset according to sex. Women (closed triangle) exhibit-
ed higher DAT activity in all the striatal subregions compared with men (open circle). Women (dotted line) exhibited a more rapid decrease 
in DAT activity in the antero-dorsal striatum (anterior caudate, p = 0.004; posterior caudate, p = 0.003; anterior putamen, p = 0.013) but not 
in the sensorimotor striatum (posterior putamen, p = 0.424; ventral putamen, p = 0.121) compared with men (solid line) [Adapted from Lee 
et al. J Mov Disord 2015;8:130-135 (45)]. C: A scatterplot showing the relationship between DAT activity in the posterior putamen and motor 
deficits according to handedness. Patients with dominant-side onset PD (closed triangle) showed lower UPDRS motor scores compared 
with nondominant-side onset PD (open circle) despite exhibiting a similar level of DAT activity in the posterior putamen (p = 0.013) [Adapted 
from Ham et al. Mov Disord 2015;30:1921-1925 (52)]. FOG: freezing of gait, PD: Parkinson’s disease, LED: levodopa-equivalent dose, 
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than male PD patients.
Hand dominance
Handedness is the most prominent human behavioral asym-
metry.46 Compared to the nondominant primary motor cortex 
(M1), the dominant M1 exhibits a greater dispersion of ele-
mentary movement representations with more profuse hori-
zontal connections.47-49 Therefore, it is conceivable that the 
dominant hemisphere could have more efficient motor net-
works with a greater neural reserve to cope with the pathologi-
cal changes related to PD. Unilateral onset and persistent 
asymmetry of motor signs are unique features of PD.50,51 To 
evaluate whether dominant-side onset PD patients showed 
greater MR compared to nondominant-side onset PD patients, 
118 PD patients with significant asymmetric motor deficits 
were included for analysis.52 Among them, dominant-side on-
set patients (n = 57) exhibited fewer motor deficits despite ex-
hibiting a similar level of DAT activity in the posterior puta-
men than the nondominant-side onset patients (n = 61) 
(Figure 3C), which suggests greater MR in dominant-side on-
set patients. 
Body mass index
Patients with PD have a lower body mass index (BMI) than 
healthy subjects, which can be traced back almost 10 years be-
fore the diagnosis of PD.53 In addition, a low BMI in PD is more 
pronounced in patients with greater disease severity.54 Therefore, 
a low BMI could be associated with PD-related pathology (i.e., 
dopamine neuronal degeneration). A total of 398 patients were 
divided into five quintile groups according to their BMI.55 This 
study demonstrated that BMI was associated with DAT activity 
in all striatal subregions (Figure 3D–I, II, III, IV, and V), which 
suggests that a lower BMI might be related to a lower density of 
nigrostriatal dopaminergic neurons in PD. In an additional 
analysis, we compared MR between the low BMI group (the first 
and second quintile group) and the high BMI group (the fourth 
and fifth quintile group). This analysis showed that the low BMI 
group exhibited greater motor deficits than the high BMI group 
after controlling for age, sex, and DAT activity in the posterior 
putamen (Figure 3D–VI). This result suggests that a low BMI in 
patients with early PD may represent low MR. 
PRECLINICAL AND CLINICAL 
PRESENTATION AND MR
Olfactory dysfunction
Olfactory dysfunction is present in approximately 70–90% of 
patients with early-stage PD and can precede the onset of mo-
tor symptoms by several years.56-58 The pathologic process of PD 
spreads from the olfactory bulb, anterior olfactory nucleus, and 
Figure 3. Demographic variables and motor reserve. D: I–V. Scatterplots showing the relationship between DAT activity in the striatal sub-
regions and BMI. BMI was positively correlated with DAT activity in the anterior putamen (r = 0.162, p = 0.001), posterior putamen (r = 0.133, 
p = 0.009), ventral striatum (r = 0.134, p = 0.008), caudate nucleus (r = 0.159, p = 0.002), and total striatum (r = 0.164, p = 0.001) [Adapted 
from Lee et al. Neurobiol Aging 2016;38:197-204 (55)]. VI. A scatterplot showing the relationship between DAT activity in the posterior puta-
men and motor deficits according to BMI. The low BMI group (the first and second quintile group) exhibited higher UPDRS motor scores 
than the high BMI group (the fourth and fifth quintile group) after controlling for age, sex, and DAT activity in the posterior putamen. DAT: 
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lower brainstem to different brain areas.59,60 Olfactory dysfunc-
tion is typically nonprogressive once motor symptoms devel-
op;57,61 thus, predetermined olfactory involvement may have an 
impact on PD progression. Furthermore, the olfactory bulb is 
the main source for neurogenesis in adults.62 Thus, patients with 
spared olfaction (i.e., normosmic PD) may have a greater po-
tential for neurogenesis and greater MR against the neuro-
pathological processes of PD compared to hyposmic PD. 
Among a total of 208 patients who performed a Cross Cultural 
Smell Identification Test (CCSIT), normosmic patients (CCSIT 
score ≥ 9; n = 53) exhibited fewer motor deficits after control-
ling for potential confounding factors, including DAT activity 
in the posterior putamen, compared to hyposmic patients (CC-
SIT score ≤ 6, n = 96) (Figure 4A).8 The LED during follow-up 
tended to be lower in normosmic compared with hyposmic PD 
patients. These findings suggest that normosmic PD is a unique 
clinical phenotype with greater MR and a more benign course 
compared to hyposmic PD.
REM sleep behavioral disorder
Rapid eye movement sleep behavior disorder (RBD) is an 
important biomarker of prodromal PD.63 Polysomnography-
proven RBD exhibits a 130-fold increased likelihood ratio for 
PD.64 Accordingly, striatal DAT activity is reduced in patients 
with idiopathic RBD compared to healthy controls.65 PD pa-
tients without RBD exhibited a different pattern of striatal 
DAT activity compared to those with RBD.66 Furthermore, a 
prospective cohort study demonstrated that the presence of 
RBD in patients with PD at baseline indicates a more rapid 
disease progression of PD.67 Therefore, PD without RBD may 
represent a benign motor phenotype of PD similar to norm-
osmic PD. Among a total of 122 patients who performed the 
RBD Screening Questionnaire (RBDSQ)68 at baseline, pa-
tients with clinically probable RBD (RBDSQ score ≥ 7, n = 
39; a cut-off of 6/7 was used to minimize the false positives 
for the presence of RBD in patients with PD69) exhibited 
greater parkinsonian motor deficits predominantly in the 
less-affected side and axial symptoms and required higher 
LEDs during the follow-up period compared to those with-
out clinically probable RBD (RBDSQ score ≤ 4, n = 58).70 
These differences in motor deficits remained significant after 
controlling for DAT activity in the putamen and other con-
founding variables (Figure 4B), suggesting that the presence 
of RBD at baseline may represent a distinct PD subtype with 
a malignant motor phenotype and low MR in individuals 
with PD.  
Depression
Depression is a representative nonmotor symptom (NMS) 
that may precede the onset of parkinsonian motor symptoms;63 
the presence of depression in early-stage PD has been proposed 
to result from the pathological involvement of the monoaminer-
gic brainstem nuclei.71 Accordingly, early accompaniment of de-
pression in PD may indicate widespread involvement of PD pa-
thologies, which subsequently may limit compensatory ability 
and reduce MR in individuals with PD. A previous study that 
showed more physical impairments in depressed than nonde-
pressed patients with PD72 supports the above hypothesis. A to-
tal of 474 patients who performed the Beck Depression Invento-
ry (BDI) at baseline were divided into tertiles based on their BDI 
score.73 The highest tertile group (BDI score ≥ 15; n = 157) 
showed more severe motor deficits and a lower level of cognitive 
performance than the lowest tertile group (BDI score ≤ 7, n = 
158). This difference in motor deficits remained significant after 
controlling for DAT activity in the posterior putamen and other 
confounding factors (Figure 4C–I). In addition, the highest ter-
tile group received higher LEDs for symptom control during fol-
low-up than the lowest tertile group after controlling for age, sex, 
and initial motor deficit severity (Figure 4C–II). These findings 
indicate that the presence of depression at baseline represents re-
duced MR in PD.
Nonmotor burden
A variety of NMS are frequently accompanied by PD, which 
occur across all stages of PD, including the prodromal stage.74,75 
The involvement of PD-related pathology in widespread brain-
stem and cortical regions could be responsible for various 
NMS.75-77 Therefore, patients with greater nonmotor burden at 
baseline may have more widespread involvement of PD pa-
thology and limited MR in PD compared to those with fewer 
nonmotor burden. A cluster analysis study has demonstrated 
that nonmotor dominant patients with PD exhibit a more rap-
id motor progression than either pure-motor or mixed motor/
nonmotor PD patients,78 which supports the above hypothesis. 
A total of 151 patients who performed the Korean version of 
Non-Motor Symptom Scale (K-NMSS)79 at baseline were clas-
sified into two groups: high nonmotor burden group (K-NMSS 
score ≥ 41, n = 71) and low nonmotor burden group (K-NMSS 
score < 41, n = 80).80 Patients in the high nonmotor burden 
group were older, had a longer disease duration, exhibited 
more severe parkinsonian motor deficits, and received higher 
doses of dopaminergic medications during follow-up than 
those in the low nonmotor burden group despite similar levels 
of striatal DAT activity. The difference in motor deficits re-
mained significant after controlling for potential confounding 
factors, including DAT activity, in the sensorimotor striatum 
(Figure 4D). These results suggest that low nonmotor burden 
at baseline represents a greater MR in PD compared to high 
178
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Figure 4. Preclinical and clinical presentation and motor reserve. A: A scatterplot showing the relationship between DAT activity in the pos-
terior putamen and motor deficits according to olfactory function. Normosmic PD patients (blue) exhibited lower UPDRS motor scores than 
hyposmic PD patients (red) at similar levels of DAT activity (p = 0.016) [Adapted from Lee et al. Neurology 2015;85:1270-1275 (8)]. B: A 
scatterplot showing the relationship between DAT activity in the posterior putamen and motor deficits according to the presence of RBD. PD 
patients with clinically probable RBD (closed circle) exhibited higher UPDRS motor scores than those without clinically probable RBD (open 
circle) at similar levels of DAT activity (p = 0.046) [Adapted from Chung et al. Eur J Neurol 2017;24:1314-1319 (70)]. C: I. A scatterplot 
showing the relationship between DAT activity in the posterior putamen and motor deficits according to the BDI scores. The highest tertile 
group (red circle) exhibited higher UPDRS motor scores than the lowest tertile group (blue circle) after controlling for DAT activity in the 
posterior putamen (p = 0.046). II. Comparison of longitudinal increases in LED according to the BDI scores. The highest tertile group re-
quired higher doses of dopaminergic medications for symptom control compared with the lowest tertile group [Adapted from Lee et al. PLoS 
One 2018;13:e0203303 (73)]. D: A scatterplot showing the relationship between DAT activity in the posterior putamen and motor deficits ac-
cording to the NMS burden. The high NMS burden group (closed circle) exhibited higher UPDRS motor scores compared with the low NMS 
burden group (open circle) at similar levels of DAT activity (p = 0.004) [Adapted from Chung et al. PLoS One 2016;11:e0161316 (80)]. DAT: 
dopamine transporter, PD: Parkinson’s disease, UPDRS: Unified Parkinson’s Disease Rating Scale, RBD: rapid eye movement sleep be-
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nonmotor burden at baseline.
NEUROIMAGING MARKERS AND MR
Dopamine depletion patterns
Selective and asymmetric involvement of the posterior puta-
men is the principal pathological feature of the nigrostriatal 
pathway in patients with PD;81-85 however, the mechanism un-
derlying this regional vulnerability remains unclear. The spatial 
patterns of striatal dopaminergic denervation are maintained 
as the disease progresses83,84 and vary extensively among indi-
viduals with PD. Therefore, the pattern of striatal dopamine 
depletion might represent a consistent and specific characteris-
tic of each patient with PD and could provide information on 
the clinical profiles; few studies have demonstrated that residu-
al dopamine in the associative/limbic and contralateral stria-
tum can act as a compensatory mechanism for parkinsonian 
motor symptoms.86,87 A total of 634 patients were divided into 
tertile groups according to their patterns of striatal dopamine 
depletion, i.e., 1) the degree of dopamine loss found in the oth-
er striatal subregions compared to the posterior putamen [in-
tersubregional ratio (ISR)] and 2) the interhemispheric asym-
metry of dopamine deficits in the posterior putamen 
[asymmetry index (AI)] (Figure 5A–I).88 The highest tertile 
group of patients with PD according to AI exhibited milder 
parkinsonian motor signs than the lowest tertile group despite 
their greater decrease in DAT activity in the more affected pos-
terior putamen (Figure 5A–II). In addition, the highest tertile 
group according to either ISR or AI values received lower dos-
es of dopaminergic medications for symptom control than the 
corresponding lowest tertile group during the follow-up period 
(> 2 years). These findings suggest that the baseline patterns of 
striatal dopamine depletion can act as a marker for MR in PD, 
while high ISR and AI values represent a greater MR.
White matter hyperintensity signals
White matter hyperintensities (WMHs) are commonly ob-
served in brain imaging studies of the healthy elderly.89 Ample 
evidence has suggested that WMHs have a clinical impact on 
motor disability in the elderly,90 which might be associated with 
interruption of frontal subcortical motor circuits.91 Moreover, 
white matter integrity appears to be related to the nigrostriatal 
synaptic dopamine function via common biological mecha-
nisms.92 Accordingly, WMH might contribute to the clinical se-
verity in patients with PD. Indeed, a number of studies have 
demonstrated that severe WMH is associated with greater mo-
tor deficits, especially axial motor impairments in patients with 
PD,93-98 whereas some studies failed to demonstrate this associa-
tion.99 Our data revealed that the PD group with moderate to 
severe WMH (n = 109) exhibited more severe motor deficits 
than the PD group with minimal WMH (n = 227) despite com-
parable striatal DAT activity.43 Furthermore, the PD group with 
moderate to severe WMH required higher doses of dopaminer-
gic medications for symptom control compared to the PD 
group with minimal WMH (Figure 5B–I). The moderate to se-
vere WMH group also exhibited an increased risk of developing 
freezing of gait (Figure 5B–II).100 These results suggest that 
baseline WMH severity can be used as an imaging marker for 
MR as well as a prognostic marker for motor outcomes in indi-
viduals with PD.
Functional brain network associated with MR
In patients with AD, several neuroimaging studies have dem-
onstrated that neural substrates of CR are closely linked to AD 
pathology-prone regions.101-106 We hypothesized that the neural 
correlates of MR in PD populations might be coupled with the 
network associated with motor function. Among 134 patients 
who performed resting state functional MRI at baseline, we cal-
culated the ‘MR estimate’ of each patient based on the UPDRS 
motor scores and DAT activity in the posterior putamen using 
a residual model with high MR estimates indicating high MR.22 
Then, we applied a network-based statistic (NBS) analysis to 
identify the functional brain network associated with the MR 
estimate (i.e., MR network) using resting-state functional MRI 
data. NBS analysis identified that the MR network comprised of 
the basal ganglia (putamen, caudate, pallidum), inferior frontal 
cortex, insula, cerebellar vermis, hippocampus, and amygdala 
(Figure 5C–I), which could share the core components of the 
network associated with motor function in PD.107-110 Patients 
with an increased degree of functional connectivity within the 
MR network exhibited a greater MR. Moreover, higher MR 
network strength (i.e., increased functional connectivity within 
the MR network) was associated with a slower longitudinal in-
crease in doses of dopaminergic medications (Figure 5C–II). 
These findings suggest that functional connectivity within the 
MR network could indicate an individual’s capacity to cope 
with neurodegenerative processes in PD.
Prognostic implications of MR
In AD populations, it is well established that patients with 
high CR exhibit a greater capacity to tolerate AD pathology but 
exhibit a more rapid cognitive decline once the critical thresh-
old is reached. This is presumably due to more advanced pa-
thologies at the critical threshold coupled with the shorter time 
frame required to reach the point when AD pathology over-
whelms cognitive function.2 However, the impact of the initial 
MR on the long-term prognosis in PD remains unclear. A total 
of 205 patients were classified into two groups based on their 
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Figure 5. Neuroimaging markers and MR. A: I. Examples of PD groups according to ISR and AI. The ISR-H exhibited a slower longitudinal 
increase in doses of dopaminergic medications than the ISR-L (p = 0.003). The AI-H exhibited milder parkinsonian motor signs than the AI-L 
despite their greater decrease in DAT activity in the posterior putamen. The AI-H group also showed a slower longitudinal increase in doses 
of dopaminergic medications than the AI-L group (p < 0.001) [Adapted from Chung et al. Clin Nucl Med 2018;43:787-792 (88)]. II. A scatter-
plot showing the relationship between DAT activity in the posterior putamen and motor deficits according to the AI value. The highest tertile 
AI group (sky-blue circle and solid line) exhibited lower UPDRS motor scores than the lowest tertile AI group (dark blue circle and dashed 
line) despite a greater decrease in DAT activity in the posterior putamen. B: WMH signals. I. Longitudinal increases in LED. The PD group 
with moderate to severe WMH received higher doses of dopaminergic medications compared with the PD group with minimal WMH [Adapt-
ed from Chung et al. Parkinsonism Relat Disord 2019;66:105-109 (100)]. II. Curves of Kaplan-Meier estimates of the onset of FOG in PD 
patients with moderate to severe WMH and matched PD patients with minimal WMH. The moderate to severe WMH group exhibited an in-
creased risk for developing FOG than the minimal WMH group (PLog-rank < 0.001). C: I. Functional brain network associated with MR (MR 
network) at a primary threshold of p-value 0.001. A network-based statistic analysis identified that the MR network is composed of the basal 
ganglia, hippocampus, amygdala, inferior frontal cortex, insula, and cerebellar vermis. II. Spaghetti plot showing longitudinal changes in 
LED according to the MR network strength. The MRN-L (lower quartile, red line) exhibited a steeper increase in LED at 1-year and 2-year 
follow-up visits than the MRN-H (upper quartile, black line) [Adapted from Chung et al. Mov Disord 2020;35:577-586 (22)]. MR: motor re-
serve, PD: Parkinson’s disease, ISR: intersubregional ratio, AI: asymmetry index, ISR-H: highest tertile group according to ISR, ISR-M: 
middle tertile group according to ISR, ISR-L: lowest tertile group according to ISR, AI-H: highest tertile group according to AI, AI-M: middle 
tertile group according to AI, AI-L: lowest tertile group according to AI, DAT: dopamine transporter, UPDRS: Unified Parkinson’s Disease 
Rating Scale, WMH: white matter hyperintensity, LED: levodopa-equivalent dose, FOG: freezing of gait, MRN-L: low MR network strength 
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MR estimate, including those with high MR (n = 65) and those 
with low MR (n = 57), which was determined by initial motor 
deficits and striatal DAT activity (Figure 6A).111 As expected, 
the low MR group exhibited higher baseline motor deficits 
than the high MR group despite having comparable levels of 
DAT activity in the posterior putamen. During the follow-up 
period, the low MR group received higher doses of dopami-
nergic medications for symptom control than the high MR 
group (Figure 6B–I). Moreover, the low MR group exhibited 
an increased risk of developing levodopa-induced dyskinesia 
and freezing of gait compared with the high MR group, which 
are important clinical milestones of disease progression in PD 
(Figure 6B–II and III). These results suggest that initial MR (i.e., 
the individual’s capacity to tolerate PD pathology) can be main-
tained with disease progression. Our observations are consis-
tent with a passive reserve model (i.e., a greater capacity of pre-
existing neural substrates) rather than an active reserve model 
(i.e., more efficient neural compensations that might result in 
more rapid progression once parkinsonian symptoms manifest) 
in PD.21,22 Therefore, factors enhancing MR (e.g., education18 
and physical activity13) may be protective against PD pathology 
throughout the disease course and can be used as preventive and 
therapeutic strategies against PD.112,113
Summary
In this review, we discussed several factors that can enhance 
or reduce the MR in patients with PD (Table 1). In particular, 
some premorbid experiences (i.e., physical activity and educa-
tion) and modifiable factors, such as BMI and WMH (which 
might be related to vascular risk factors), could modulate an in-
Figure 6. Prognostic implications of MR. A: Classification of the patients with PD according to MR. MR estimates of each patient were cal-
culated based on the baseline UPDRS motor score and DAT activity in the posterior putamen. The general linear model was used to predict 
the UPDRS motor scores using age, disease duration, and the natural logarithm of DAT activity in the posterior putamen. The solid line 
(black) indicates the regression line of the general linear model, and the dotted lines (red) indicate the range of ± 0.5 standard deviations of 
the fitted values. PD-H (standardized residuals < -0.5); PD-L (standardized residuals > 0.5). B: I. Longitudinal increases in LED. The low 
MR group received higher doses of dopaminergic medications for symptom control compared with the high MR group during the follow-up 
period. II. Curves of Kaplan-Meier estimates of the onset of levodopa-induced dyskinesia in PD groups. The low MR group exhibited an in-
creased risk for the early development of levodopa-induced dyskinesia compared with the high MR group (PLog-rank < 0.001). III. Curves of 
Kaplan-Meier estimates of the onset of FOG in the PD groups. The low MR group exhibited an increased risk of developing FOG compared 
to the high MR group (PLog-rank = 0.045) [Adapted from Chung et al. Neurobiol Aging 2020;92:1-6 (111)]. MR: motor reserve, PD: Parkinson’s 
disease, UPDRS: Unified Parkinson’s Disease Rating Scale, DAT: dopamine transporter, PD-H: PD group with high MR, PD-L: PD group 
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Table 1. Summary of factors affecting MR in patients with PD
MR-related factors Comment
Modifiable
Physical activity Premorbid exercise → MR↑
Education Higher education attainment →  
  MR↑
Smoking No association with MR
BMI Low BMI → MR↓
WMH Moderate to severe WMH → MR↓
Nonmodifiable
Age Old age → MR↓
Sex No association with MR
Hand dominance Dominant-side-onset PD → MR↑
Olfactory dysfunction Normosmic PD → MR↑
RBD Presence of RBD → MR↓
Depression Presence of depression → MR↓
Nonmotor burden High nonmotor burden → MR↓
Striatal DAT loss pattern Antero-posterior gradient ↑,  
  asymmetry ↑ → MR↑ 
MR: motor reserve, PD: Parkinson’s disease, BMI: body mass index, 
WMH: white matter hyperintensity, RBD: rapid eye movement sleep be-
havior disorder, DAT: dopamine transporter.
dividual’s capacity to tolerate PD pathology, which can be main-
tained throughout disease progression. Therefore, modification 
of these MR-related factors may be a reasonable treatment 
strategy for delaying parkinsonian symptom onset or improv-
ing the long-term motor outcomes of PD. Further studies are 
also needed to determine whether an active or passive reserve 
model will work in the strategy of enhancing each MR proxy.
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